Key points are not available for this paper at this time.
Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol Myers Squibb and others; CheckMate 9ER ClinicalTrials.gov number, NCT03141177.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Toni K. Choueiri
Thomas Powles
Mauricio Burotto
New England Journal of Medicine
Harvard University
National Institutes of Health
University College London
Building similarity graph...
Analyzing shared references across papers
Loading...
Choueiri et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d91684d8690e49a78358b6 — DOI: https://doi.org/10.1056/nejmoa2026982
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: